Video

Q&A With Gerald Smetana, MD, from Beth Israel Deaconess Medical Center: Weighing Benefits of Vorapaxar for Patients

Author(s):

With primary care physicians treating such a broad spectrum of conditions they also have a number of medications they can prescribe to help their patients. While some of these are more beneficial than others it is important to consider which might be more effective for patients.

With primary care physicians treating such a broad spectrum of conditions they also have a number of medications they can prescribe to help their patients. While some of these are more beneficial than others it is important to consider which might be more effective for patients.

Gerald Smetana, MD, from Beth Israel Deaconess Medical Center discussed four medications during the American College of Physicians Internal Medicine Meeting in Boston. One medication discussed, Vorapaxar, has been approved to help patients avoid a second cardiovascular event.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Experts' Perspectives: Top Stories in Cardiology for 2024
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
© 2025 MJH Life Sciences

All rights reserved.